http://ijcrpp.com/index.php/ijcrpp/issue/feed International Journal of Current Research in Physiology and Pharmacology 2021-03-07T19:45:39-05:00 Journal Office journaloffice@sumathipublications.com Open Journal Systems http://ijcrpp.com/index.php/ijcrpp/article/view/37 Artificial Intelligence in Pharma 2021-03-05T09:52:55-05:00 Keziah Ann Babu keziahannbabu@gmail.com Shirlin MS shinushirley@gmail.com Manjula Devi AS hari1509@gmail.com <p>This paper aims to provide a better understanding of the possible applications of Artificial Intelligence (AI) in the field of Pharmacy. Artificial intelligence basically involves complex information processing. It enables machines to carry out certain functions which were originally done by human and which required human intellect. Over the past few years, the use of artificial intelligence in the pharma has grown unimaginably and is now able to revolutionize the way drugs are discovered and handled. AI is capable of impacting the field of pharmacy at multiple levels. Pharmacy and medical education, drug development, personalization of drug therapy, drug safety, rational drug use, manufacture and formulation of dosage forms are areas of impact by AI. The fact that AI can displace humans at their own tasks is a matter of concern. Although there are ethical concerns regarding the implementation of AI in healthcare, it can be assured that no machine or system can replace many of the humanitarian duties.</p> 2021-03-05T00:00:00-05:00 Copyright (c) 2021 Keziah Ann Babu, Shirlin MS, Manjula Devi AS http://ijcrpp.com/index.php/ijcrpp/article/view/39 Effect of sildenafil citrate on prediabetic and diabetic albino rats treated with metformin 2021-03-07T19:45:39-05:00 ahmed mohmed taha ahmadtaha669@yahoo.com Haredy Hassan Haredy admin@hotmail.com Ahmed Ghareip admin@hotmail.com Ahmed El sayed Nour el-deen admin@hotmail.com Yasser M Ashour admin@hotmail.com <p>Diabetes Miletus (DM) is a global epidemic disease. It is estimated that there are already 415 million adults aged 20–79 years diabetics worldwide. Sildenafil citrate is a phosphodiesterase type 5 (PDE5) inhibitor, which increases cyclic guanosine monophosphate (cGMP) and metformin (MET) is a biguanide used for the treatment of type 2 diabetes which increases peripheral insulin sensitivity.</p> <p><strong>Aim</strong>: This study aims to assess the effect of sildenafil citrate and metformin on lipid profile and glycemic control in diabetic and prediabetic albino rats.</p> <p><strong>Materials and methods</strong>: Adult male albino rats are used and divided into nine groups each group consists of 10 rats, diabetes is induced by feeding a high-fat diet (HFD) for an initial period of 2 weeks followed by a single intraperitoneal injection of (35 mg/kg) Streptozotocin. Prediabetes is induced by feeding (HFD) and glucose in water for a period of 2 weeks. Sildenafil was given in a dose of (5 &amp;10 mg/kg/day orally for 4 weeks), metformin was given in a dose of (50 &amp;100 mg/kg/day orally for 4 weeks) using oral gavages to normal healthy rats, diabetic and prediabetic rats. Blood samples were collected after 4 weeks of treatment in all experimental groups.</p> <p><strong>Results</strong>: Combined administration of sildenafil and metformin on diabetic rats improving hyperglycemia, oxidative stress, and hyperlipidemia induced by streptozotocin than the administration of metformin or sildenafil alone.</p> <p><strong>Conclusion</strong>: Sildenafil has beneficial effects against some diabetic complications. The present study showed that sildenafil with metformin has beneficial effects against diabetic complications.</p> 2021-03-07T00:00:00-05:00 Copyright (c) 2021 Ahmed Mohmed Taha, Haredy Hassan Haredy, Ahmed Ghareip, Ahmed El sayed Nour el-deen, Yasser M Ashour